No­vo Nordisk sub­sidiary to build $220M API fa­cil­i­ty for chron­ic dis­ease drugs

No­vo Nordisk Phar­mat­e­ch is build­ing a new fa­cil­i­ty in Den­mark to ex­pand ca­pac­i­ty for raw ma­te­r­i­al pro­duc­tion due to “sig­nif­i­cant­ly high­er de­mand” from its par­ent …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER